The transcription factor ZNF217 drives hepatocellular carcinoma progression by activating de novo lipid synthesis via FASN upregulation [0.03%]
转录因子ZNF217通过上调FASN激活从头脂质合成促进肝细胞癌进展
Yihui Fang,Ting Zhang,Tianxing Ye et al.
Yihui Fang et al.
Background: Metabolic reprogramming, particularly enhanced lipid synthesis, is a hallmark of cancer that supports tumor growth and progression. However, the transcriptional regulators controlling this process in hepatocel...
Efficacy and safety of transarterial chemoembolization (TACE) with tislelizumab and tyrosine kinase inhibitors versus TACE for intermediate and advanced HCC [0.03%]
替雷利珠单抗或酪氨酸激酶抑制剂联合经动脉化疗栓塞治疗中晚期肝细胞癌的疗效和安全性：倾向评分匹配分析
Saikang Tang,Xue Yan,Tao Gong et al.
Saikang Tang et al.
Background & aims: Transarterial chemoembolization (TACE) combined with targeted therapy and immunotherapy is a promising approach for intermediate and advanced hepatocellular carcinoma (HCC). This study aimed to compare ...
Glypican-1 targeted nanoplatform for pancreatic ductal adenocarcinoma: interpreting findings [0.03%]
面向胰腺导管腺癌的 Glypican-1 目标纳米平台：解释研究结果
Arman Abroumand Gholami,Djalolidin Mansurov,Tolib Bekmirov
Arman Abroumand Gholami
Phenotypic heterogeneity in carriers of a pathogenic MSH2 variant: implications for the diagnosis of Lynch syndrome [0.03%]
MSH2基因突变携带者表型异质性及其对林奇综合征诊断的影响
Tuna Apuhan,Oguzhan Demir,Zeynep Sagnak Yilmaz et al.
Tuna Apuhan et al.
Lynch syndrome is an inherited cancer predisposition syndrome caused by germline pathogenic variants in mismatch repair (MMR) genes and is primarily associated with colorectal and endometrial cancers. Classically, Lynch syndrome-associated ...
Alexandra Monteiro,Diana Pádua,Catarina Gonçalves et al.
Alexandra Monteiro et al.
Cancer is a multifactorial disease, driven by dysregulation of cellular processes that are controlled by the complex influence of DNA and RNA-level regulatory mechanisms. Epitranscriptomics has surfaced as a prominent field in cancer resear...
Prognostic influence of small leucine-rich proteoglycans on serous ovarian cancer [0.03%]
小亮氨酸丰富糖蛋白对浆液性卵巢癌预后的影响
H Surmann,A Bartha,B Győrffy et al.
H Surmann et al.
Purpose: Ovarian cancer is one of the most lethal cancers in women worldwide. To be able to offer successful treatment and improve the prognosis, knowledge of factors influencing the tumor microenvironment is indispensabl...
De-escalating axillary surgery in early breast cancer: external validation of a retrospective cohort [0.03%]
早期乳腺癌腋窝手术降级的外部验证：一项回顾性队列研究
Mathilde Landry,Amelia Favier,Feriel Ksantini et al.
Mathilde Landry et al.
Background: Sentinel lymph node biopsy (SLNB) is the standard for axillary staging in early breast cancer, yet its relevance is increasingly questioned in patients with favorable tumor biology when nodal status does not i...
Diagnostic performance of the NI-RADS system for detecting recurrence in head and neck squamous cell carcinoma: a monocentric pilot study [0.03%]
评估影像报告和数据系统在头颈部鳞癌复发检测中的诊断性能：单中心初步研究
Sara Greco,Ilaria Villanova,Nicola Maggialetti et al.
Sara Greco et al.
Background: This pilot study evaluates the diagnostic performance and clinical relevance of the Neck Imaging Reporting and Data System (NI-RADS) in the post-treatment surveillance of patients with head and neck squamous c...
Investigation of a GPC1-targeted and LIFU-responsive nanoplatform with ADV effect for visualized chemo-sonodynamic therapy against pancreatic ductal adenocarcinoma [0.03%]
用于可视化化疗与声动力治疗胰腺导管腺癌的GPC1靶向和LIFU响应型载药纳米平台研究
Bo Ren,Gang Quan,Hanmei Li et al.
Bo Ren et al.
Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies. Regardless of surgical resection, chemotherapy acts as the first-line treatment for PDAC. However, the clinical outcomes are...
Investigation of a methylated BCAT1 and IKZF1 circulating tumour DNA blood test for monitoring treatment response in patients with colorectal cancer [0.03%]
结直肠癌患者甲基化BCAT1和IKZF1循环肿瘤DNA血液检测用于监测治疗反应的研究
Rafha Rafeeu,Erin L Symonds,Michael Z Michael et al.
Rafha Rafeeu et al.
Purpose: Colorectal cancer (CRC) treatment failure results in high mortality. The current CRC treatment response monitoring blood biomarker carcinoembryonic antigen (CEA) lacks specificity. Methylated BCAT1/IKZF1 circulat...